Welcome to our dedicated page for GRAY news (Ticker: GRAY), a resource for investors and traders seeking the latest updates and insights on GRAY stock.
The GRAY news archive on Stock Titan covers the historical public communications of Graybug Vision, Inc., which previously traded on Nasdaq under the symbol GRAY. Company press releases describe Graybug as a clinical-stage biopharmaceutical company focused on developing medicines for ocular diseases, including vision-threatening disorders of the retina, optic nerve, and cornea.
News items in this archive include updates on Graybug’s investigational pipeline, such as GB-102 for wet age-related macular degeneration, GB-401 for primary open-angle glaucoma, and gene therapy and sustained-release candidates like GB-501, GB-601, and GB-701. Releases also document participation in ophthalmology conferences and scientific meetings where the company presented preclinical and clinical data related to its programs.
Another important theme in the GRAY news history is corporate strategy. Graybug announced a review of strategic alternatives, outlining potential options such as a merger or company sale, followed by cost-containment measures and changes to its development activities. Subsequent news detailed a definitive merger agreement with CalciMedica Inc., an all-stock transaction intended to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on life-threatening inflammatory diseases.
The archive further records the name and trading symbol change from Graybug Vision, Inc. (GRAY) to CalciMedica, Inc. (CALC) on the Nasdaq Global Market, undertaken in connection with the merger. Readers using this page can follow the historical progression from Graybug’s focus on ophthalmology through its strategic review and combination with CalciMedica. For ongoing developments after the name and ticker change, company communications direct attention to CalciMedica, Inc. under the symbol CALC.
Investors and researchers can use this GRAY news collection as a historical reference to understand Graybug’s former pipeline, its clinical and preclinical milestones, and the sequence of events leading to its merger and rebranding as CalciMedica, Inc.
Graybug Vision, a clinical-stage biopharmaceutical firm, has announced that its CEO, Fred Guerard, will engage in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 3:40 p.m. ET. This event highlights Graybug's commitment to developing innovative treatments for chronic retinal diseases. The chat can be accessed via a live webcast on Graybug's investor relations page, with a replay available for 14 days post-event. Graybug's lead product, GB-102, aims for extended dosing regimens, targeting conditions like wet age-related macular degeneration.
Graybug Vision, Inc. (Nasdaq: GRAY) announced the appointment of Bettina Maunz as Chief People Officer, effective immediately. Maunz, who has been a consultant since August 2019, will also lead communications and contribute to the executive team. CEO Frederic Guerard emphasized her leadership experience will enhance employee engagement and team performance. Maunz's previous roles include senior positions in communications at Novartis and Alcon, where she significantly impacted organizational culture and corporate responsibility. Graybug is focused on innovative treatments for retinal and optic nerve diseases.
Graybug Vision (Nasdaq: GRAY) announced the completion of patient treatment in its Phase 2b ALTISSIMO trial for GB-102, aimed at addressing wet age-related macular degeneration (AMD). Of the 56 enrolled patients, 50 completed the 12-month treatment phase, with 58% opting for a six-month extension. Topline data is expected in Q2 2021, which will assess the drug's durability and safety compared to traditional treatments requiring up to 12 injections yearly. GB-102 is designed for biannual administration, potentially easing treatment burdens for AMD patients.
Graybug Vision, a clinical-stage biopharmaceutical company, announced CEO Fred Guerard will participate in a fireside chat ahead of the virtual Piper Sandler Healthcare Conference on December 1-3, 2020. The recorded chat will be accessible starting November 23, 2020, via the company's website and will remain available for 14 days post-conference. Graybug focuses on developing innovative treatments for retinal diseases, utilizing proprietary ocular delivery technologies for extended drug release, including lead candidate GB-102 for age-related macular degeneration.
Graybug Vision, Inc. (Nasdaq: GRAY) reported a net loss of $4.7 million for Q3 2020, improving from $10.2 million in Q3 2019. The company's net loss for the nine months ended September 30, 2020, was $18.4 million, down from $26.8 million a year prior. Graybug raised over $92 million from its IPO, enhancing its cash reserves to $95 million. The lead product candidate, GB-102, is in Phase 2b development and aims to reduce treatment frequency for retinal diseases. Major milestones are anticipated in 2021, including the initiation of Phase 3 trials.
Graybug Vision (Nasdaq: GRAY) announced the appointment of three new Board members: Christina Ackermann, Eric Bjerkholt, and Julie Eastland. They replace former members Emmett Cunningham, Chau Khuong, and Cameron Wheeler, enhancing the board's expertise in healthcare and biotechnology. Graybug is entering a pivotal phase following its initial public offering, aiming to advance its pipeline of ophthalmic drugs. Key products include GB-102, targeting retinal diseases with a six-month dosing regimen, and GB-401 for glaucoma with a similar dosing schedule.
Graybug Vision announced the pricing of its upsized initial public offering (IPO) of 5,625,000 shares at $16.00 per share, aiming for gross proceeds of $90 million. The shares will trade on Nasdaq under the symbol GRAY starting September 25, 2020. The offering includes a 30-day option for underwriters to purchase an additional 843,750 shares. Graybug, focused on innovative treatments for retinal diseases, plans to utilize the funds to further develop its drug candidates, enhancing treatment regimens for chronic vision-threatening conditions.